RC
TEVA icon

Roundview Capital’s Teva Pharmaceuticals TEVA Stock Holding History

Roundview Capital’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-58,709
Closed -$1.19M – 345
2025
Q3 		$1.19M Hold
58,709
– – 0.08% 202
2025
Q2 		$984K Hold
58,709
– – 0.07% 215
2025
Q1 		$902K Hold
58,709
– – 0.07% 209
2024
Q4 		$1.29M Buy
58,709
+1,850
+3% +$33.7K 0.09% 188
2024
Q3 		$1.02M Buy
56,859
+6,000
+12% +$105K 0.07% 216
2024
Q2 		$826K Hold
50,859
– – 0.07% 222
2024
Q1 		$718K Buy
50,859
+24,300
+91% +$306K 0.06% 232
2023
Q4 		$277K Buy
+26,559
New +$248K 0.03% 284

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Roundview Capital's TEVA Position: Q4 2025 in Review

Roundview Capital sold out of Teva Pharmaceuticals (TEVA) in Q4 2025, closing a stake of 58,709 shares — an estimated $1.19M sold.

Roundview Capital first reported a position in TEVA in Q4 2023 and held it in 8 quarters. The position peaked at $1.29M in Q4 2024. 631 funds tracked by Wall St. Rank hold TEVA as of Q4 2025.

  • Roundview Capital reported no remaining Teva Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • Roundview Capital sold 58,709 Teva Pharmaceuticals shares in Q4 2025, an estimated $1.19M.
  • Roundview Capital first reported a position in Teva Pharmaceuticals in Q4 2023 and held it in 8 quarters.
  • Roundview Capital's Teva Pharmaceuticals position peaked at $1.29M in Q4 2024.
  • 631 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2025.

Based on Roundview Capital's 13F filing for Q4 2025, filed 9 Feb 2026.